Saturday 14 February 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Conference News
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Scientists link gene to Rolandic epilepsy

Scientists link gene to Rolandic epilepsy

9 February 2009

Investigators at the USA's Columbia University Medical Center have published the results of a study that has found the first gene linked to  the most common type of epilepsy, called Rolandic epilepsy, in the  European Journal of Human Genetics .

In the study, the scientists searched the entire genome of 38 families  and found a region on chromosome 11 that was linked with Rolandic  epilepsy. Then, by comparing this region in people with the disease to  unaffected controls (255 people in total), the researchers pinpointed  the gene, called ELP4.

The findings also offer possible insights into the causes of  attention-deficit hyperactivity disorder, speech dyspraxia and  developmental coordination disorder. Children with these developmental  disorders often have the same "spiky" brainwave pattern that is present  in children with Rolandic epilepsy. Understanding how the ELP4 gene is  related to the brainwave pattern may help researchers uncover the causes  of these disorders.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

Withdrawal of EU approvals for levamisole medicines recommended
Pharmaceutical
Withdrawal of EU approvals for levamisole medicines recommended
13 February 2026
Pharmaceutical
Vertex veers upwards on impressive results
13 February 2026
Pharmaceutical
Serum Institute of India inks deal with Oxford University
13 February 2026
Biotechnology
Moderna tops Q4 2025 EPS by 51c, beats on revenue
13 February 2026
Pharmaceutical
Breztri asthma results published with filings under review
13 February 2026
Biotechnology
Immunic prices private placement of up to $400 million
13 February 2026
Biosimilars
STADA and Bio-Thera win EC nod for Simponi biosimilar
13 February 2026

Company Spotlight

Upstream Bio
A clinical-stage biotechnology company developing long-acting biologics for severe inflammatory respiratory diseases. Its pipeline is anchored by verekitug, a monoclonal antibody that antagonizes the thymic stromal lymphopoietin (TSLP) receptor.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze